A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 2,968,034 shares of CRSP stock, worth $142 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
2,968,034
Previous 3,151,514 5.82%
Holding current value
$142 Million
Previous $170 Million 18.06%
% of portfolio
0.1%
Previous 0.13%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$44.62 - $62.75 $8.19 Million - $11.5 Million
-183,480 Reduced 5.82%
2,968,034 $139 Million
Q2 2024

Jul 19, 2024

SELL
$51.17 - $68.18 $6 Million - $8 Million
-117,271 Reduced 3.59%
3,151,514 $170 Million
Q1 2024

Apr 19, 2024

SELL
$60.67 - $89.12 $6.13 Million - $9 Million
-100,977 Reduced 3.0%
3,268,785 $223 Million
Q4 2023

Jan 30, 2024

SELL
$38.62 - $72.18 $3.7 Million - $6.91 Million
-95,708 Reduced 2.76%
3,369,762 $211 Million
Q3 2023

Oct 30, 2023

SELL
$45.39 - $59.0 $3.08 Million - $4.01 Million
-67,887 Reduced 1.92%
3,465,470 $157 Million
Q2 2023

Jul 31, 2023

SELL
$43.47 - $67.77 $19.1 Million - $29.8 Million
-439,823 Reduced 11.07%
3,533,357 $198 Million
Q1 2023

Apr 27, 2023

SELL
$41.0 - $56.12 $1.37 Million - $1.87 Million
-33,296 Reduced 0.83%
3,973,180 $180 Million
Q4 2022

Jan 30, 2023

SELL
$39.19 - $65.67 $10 Million - $16.8 Million
-256,260 Reduced 6.01%
4,006,476 $163 Million
Q3 2022

Oct 21, 2022

SELL
$61.1 - $83.78 $19.6 Million - $26.9 Million
-321,362 Reduced 7.01%
4,262,736 $279 Million
Q2 2022

Jul 26, 2022

SELL
$43.23 - $73.83 $1.54 Million - $2.63 Million
-35,649 Reduced 0.77%
4,584,098 $279 Million
Q1 2022

Apr 27, 2022

BUY
$53.19 - $79.24 $246 Million - $366 Million
4,619,747 New
4,619,747 $290 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.74B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Sumitomo Mitsui Trust Holdings, Inc. Portfolio

Follow Sumitomo Mitsui Trust Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.